MOTS-c Dosage Chart: Daily Microdose or Cycled Pulse, Which One Fits Your Goal?

Search "MOTS-c dosage chart" and you'll find five different charts with five different numbers, and none of them agree. That's not because someone did the math wrong. It's because there are two completely different dosing philosophies floating around, and most guides mash them together like they're the same thing.

Quick disclaimer: this isn't medical advice. MOTS-c is a research compound, not an FDA-approved drug, and no published human dosing chart exists. Everything below comes from animal research and how the research community talks about using it, not a prescription. Talk to a doctor before changing anything about your health routine.

Once you separate the two approaches, the confusion mostly disappears. The real question isn't "what's the right dose", it's "which of these two things are you actually trying to do."

The Two MOTS-c Protocols Everyone Confuses

MOTS-c is a small peptide made from a piece of mitochondrial DNA. Researchers first got interested because it seemed to help mice regulate blood sugar and stay metabolically younger as they aged (Kim et al., 2018). Since then, two separate dosing patterns have shown up, one in the science, one in the research community, and they answer different questions.

Option A: The Daily Low-Dose Protocol. Small amounts, injected every day or nearly every day, meant to keep a steady baseline signal running in the background.

Option B: The Cycled Pulse Protocol. Larger amounts, injected two or three times a week (or in short blocks like five days on, two days off), meant to create a bigger spike followed by a break.

The single question that separates them: are you trying to maintain a constant low-level signal, or trigger a bigger, temporary stress response and then let the body recover? Those are two different jobs, and they call for two different dosing shapes.

Who Should Consider the Daily Low-Dose Protocol?

This approach fits people whose goal is steady, background metabolic support rather than a dramatic short-term push. It's the closer analog to how MOTS-c behaves naturally, mitochondria release it continuously in response to everyday stress, not in occasional bursts (Reynolds et al., 2021).

Who it suits: people prioritizing consistency over intensity, and people who want to avoid the bigger injection-site reactions that sometimes come with higher single doses.

The tradeoff: daily injections mean more sticks, more logistics, and, because the dose per injection is smaller, a slower ramp to whatever effect you're tracking. It's a marathon approach, not a sprint.

Who Should Consider the Cycled Pulse Protocol?

This approach mirrors something specific researchers found: MOTS-c levels in the blood spike sharply right after intense exercise, then drop back down (Reynolds et al., 2021). The cycled protocol tries to recreate that spike-and-recovery pattern artificially, with a bigger dose a few times a week instead of a small dose every day.

Who it suits: people who want to mimic that exercise-triggered pulse, particularly around training days, and people who'd rather deal with fewer total injections even if each one is a bigger stick.

The tradeoff: bigger doses mean a higher chance of noticing injection-site irritation, and, because there's no published human safety data for MOTS-c at any dose, bigger amounts also mean less room for error if something goes wrong. This is the more aggressive of the two paths, and "aggressive" here means less studied, not more effective.

What Does the Research Actually Say About MOTS-c Dosing?

Here's the part that matters most, and it's the part most dosage charts skip: almost everything we know about MOTS-c dosing comes from mice, not people.

In the studies researchers actually ran, mice were typically given MOTS-c by injection at doses measured in milligrams per kilogram of body weight, a range that, scaled up to a 180-pound adult, would land somewhere in the low milligram range per dose (Reynolds et al., 2021). That scaling math is where every "human" dosage chart on the internet actually comes from. Nobody ran a clinical trial in people and published the results, at least not yet.

That gap matters for the daily-vs-cycled decision too. The mouse studies that found exercise-linked benefits used repeated dosing over weeks, not a single big injection. That's a point in favor of some kind of ongoing schedule, daily or cycled, over one-off use, but it doesn't settle which schedule shape is "correct," because the mice weren't split into a daily group and a cycled group and compared.

In plain terms: the science tells us MOTS-c does something interesting in animals over time. It doesn't yet tell us whether daily or cycled dosing is better in humans. That call is currently being made by the research community based on how MOTS-c behaves biologically, not by a head-to-head human trial.

MOTS-c Dosage Chart: Side-by-Side Comparison

Factor	Daily Low-Dose Protocol	Cycled Pulse Protocol
Frequency reported	Once daily or 6x/week	2–3x/week, or short blocks (e.g., 5 days on/2 off)
Amount per injection	Smaller	Larger
Total weekly exposure	Similar or slightly lower	Similar or slightly higher
Injection site reactions	Generally milder, more frequent	Can be more noticeable, less frequent
Best mimics	Ongoing background signal	Exercise-triggered spike pattern
Logistics burden	Higher (daily commitment)	Lower (fewer total injections)
Human safety data	None published either way	None published either way

Every number in circulation is an extrapolation from animal weight-based dosing, not a clinical dose established in people. Treat any specific milligram figure you see, including in this article, as a research community reference point, not a verified human dose.

Which Protocol Should You Actually Pick?

If forced to choose, the daily low-dose approach is the more conservative starting point for most people exploring MOTS-c as a research compound. Smaller amounts per injection mean less exposure per dose while you're still in "figuring out how your body responds" territory, and it more closely follows the "steady signal" pattern the earliest human-relevant studies focused on.

The recommendation flips if your interest is specifically tied to exercise or training, the cycled protocol makes more biological sense in that context, since it's trying to copy a pattern (the post-exercise MOTS-c spike) that's actually been measured in research. If your goal has nothing to do with training and everything to do with a steady baseline routine, cycling doesn't buy you much and just adds bigger doses without a clear reason.

Either way, this is a decision to make with a healthcare provider who knows your full history, not a chart, including this one.

Frequently Asked Questions

Is MOTS-c FDA-approved? No. MOTS-c is not FDA-approved for human use. It's classified as a research compound, and any dosing information, including the ranges discussed here, comes from animal research and research community reporting, not clinical trials in people.

Can you switch between the daily and cycled protocols? There's no research answering this directly. Switching mid-stream just means you have even less data to interpret your own response by, since you're changing the variable you'd want to track. Most people trying to make sense of their own results pick one approach and stick with it long enough to actually notice a pattern.

Does MOTS-c need to be cycled off completely at some point? This is a common question borrowed from other peptide protocols, and it's a reasonable one to ask your provider, but there's no published human data specific to MOTS-c that answers it. If you're weighing on/off cycling in general, this peptide cycling guide covers the broader reasoning peptide users apply, though it isn't MOTS-c-specific.

How is MOTS-c usually prepared before injection? Like most research peptides, MOTS-c typically comes as a lyophilized (freeze-dried) powder that needs to be mixed with a liquid before use. This guide on reconstituting peptides walks through that process step by step.

Is MOTS-c the same thing as a weight-loss peptide like retatrutide or semaglutide? No, and this mix-up happens a lot. MOTS-c works through mitochondrial signaling, not the GLP-1 pathway that drugs like semaglutide use. This comparison piece breaks down how the two categories actually differ.

Quick Comparison Recap

• Daily Low-Dose Protocol = smaller amounts, more frequent injections, mimics a steady background signal. Best starting point for most people exploring MOTS-c.
• Cycled Pulse Protocol = larger amounts, fewer injections, mimics the exercise-triggered spike seen in animal studies. Makes more sense if your interest is training-related.
• Neither has published human safety or dosing data. Every number you've seen elsewhere is scaled from mouse studies, not verified in people.
• The real decision driver is your goal, steady baseline vs. exercise-linked pulse, not which chart looks more official.
• If you're using any peptide dosing calculator or chart, it's worth understanding how those tools actually work before trusting the number it spits out.

Note: MOTS-c is classified as a research compound and is not FDA-approved for human use. The information above is based on preclinical (animal) research and how the research community discusses dosing, not clinical guidance. This is not a recommendation to use this compound. Consult a qualified healthcare provider before making any decisions about your health.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. This article shares published research and general research community reporting, not medical recommendations.

Sources

1. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity, Physiological Reports, Kim et al.
2. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis, Nature Communications, Reynolds et al., 2021
3. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance, Sports Medicine, 2026